An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Name: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Published: 2021
License: Public Domain

Novartis Pharmaceuticals · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

prostatic neoplasms, lutetium-177 psma-617, 177lu-psma-617, androgen receptor-directed therapy, ardt, androgen deprivation therapy, adt, metastatic hormone sensitive prostate cancer, mhspc, radiographic progression free survival, rpfs, prostate-specific membrane antigen

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 848895
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.